NO20052814L - Cytomodulerende peptider for behandling av interstitielle cystitt - Google Patents

Cytomodulerende peptider for behandling av interstitielle cystitt

Info

Publication number: NO20052814L
Authority: NO; Norway
Prior art keywords: treatment; interstitial cystitis; cytomodulatory; peptides; modulation
Prior art date: 2002-11-15

Application number

NO20052814A

Other languages

English (en)

Norwegian (no)

Other versions

NO20052814D0 (no

Inventor

Alexis E Te

Timothy Fong

Original Assignee

Sangstat Medical Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-11-15

Filing date

2005-06-10

Publication date

2005-08-04

2005-06-10 Application filed by Sangstat Medical Corp filed Critical Sangstat Medical Corp

2005-06-10 Publication of NO20052814D0 publication Critical patent/NO20052814D0/no

2005-08-04 Publication of NO20052814L publication Critical patent/NO20052814L/no

Links

208000005615 Interstitial Cystitis Diseases 0.000 title abstract 3
102000004196 processed proteins & peptides Human genes 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 title 1
238000000034 method Methods 0.000 abstract 3
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract 2
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 abstract 1
108090000695 Cytokines Proteins 0.000 abstract 1
102000004127 Cytokines Human genes 0.000 abstract 1
108010025020 Nerve Growth Factor Proteins 0.000 abstract 1
102000015336 Nerve Growth Factor Human genes 0.000 abstract 1
102100024304 Protachykinin-1 Human genes 0.000 abstract 1
101800003906 Substance P Proteins 0.000 abstract 1
230000004888 barrier function Effects 0.000 abstract 1
208000029162 bladder disease Diseases 0.000 abstract 1
239000008280 blood Substances 0.000 abstract 1
210000004369 blood Anatomy 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
229960001340 histamine Drugs 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
229940053128 nerve growth factor Drugs 0.000 abstract 1
230000002485 urinary effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/046—Tachykinins, e.g. eledoisins, substance P; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Urology & Nephrology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO20052814A 2002-11-15 2005-06-10 Cytomodulerende peptider for behandling av interstitielle cystitt NO20052814L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US42668402P	2002-11-15	2002-11-15
US47083903P	2003-05-15	2003-05-15
PCT/US2003/037043 WO2004045554A2 (fr)	2002-11-15	2003-11-17	Peptides de cytomodulation permettant de traiter la cystite interstitielle

Publications (2)

Publication Number	Publication Date
NO20052814D0 NO20052814D0 (no)	2005-06-10
NO20052814L true NO20052814L (no)	2005-08-04

Family

ID=32329122

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20052814A NO20052814L (no)	2002-11-15	2005-06-10	Cytomodulerende peptider for behandling av interstitielle cystitt

Country Status (13)

Country	Link
US (1)	US7671026B2 (fr)
EP (1)	EP1594519A4 (fr)
JP (1)	JP2006516546A (fr)
KR (1)	KR20050086676A (fr)
AU (1)	AU2003294357A1 (fr)
BR (1)	BR0316290A (fr)
CA (1)	CA2505922A1 (fr)
CO (1)	CO5640064A2 (fr)
MA (1)	MA27607A1 (fr)
MX (1)	MXPA05005101A (fr)
NO (1)	NO20052814L (fr)
RU (1)	RU2005118425A (fr)
WO (1)	WO2004045554A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100055113A1 (en) *	2006-07-27	2010-03-04	The University Of Maryland, Baltimore	Cellular receptor for antiproliferative factor
KR101863136B1 (ko) *	2008-01-24	2018-05-31	에스퍼란스 파마슈티컬스, 인코포레이티드	용해 도메인 융합 구성물 및 이를 제조하고 사용하는 방법
EP2328603A4 (fr)	2008-08-18	2013-01-02	Univ Maryland	Dérivés d'apf et méthodes d'utilisation afférentes
WO2012048721A1 (fr)	2010-10-14	2012-04-19	Xigen S.A.	Utilisation d'inhibiteurs peptidiques, aptes à pénétrer dans les cellules, de la voie de transduction du signal jnk pour le traitement de maladies oculaires inflammatoires chroniques ou non-chroniques
US20160304617A1 (en)	2013-06-17	2016-10-20	Asana Biosciences, Llc	5t4-targeted immunofusion molecule and methods
WO2014206426A1 (fr) *	2013-06-26	2014-12-31	Xigen Inflammation Ltd.	Nouvelle utilisation des molécules inhibitrices de la jnk pour le traitement de diverses maladies
WO2014206427A1 (fr)	2013-06-26	2014-12-31	Xigen Inflammation Ltd.	Nouvelle utilisation d'inhibiteurs de peptides à perméabilité cellulaire dans la voie de transduction du signal jnk pour le traitement de diverses maladies
WO2015197097A1 (fr)	2014-06-26	2015-12-30	Xigen Inflammation Ltd.	Nouvelle utilisation pour des molécules inhibitrices de la jnk, pour le traitement de diverses maladies
AU2015281361A1 (en) *	2014-06-26	2016-11-17	Xigen Inflammation Ltd.	New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
US10859579B2 (en) *	2016-03-31	2020-12-08	William Beaumont Hospital	Methods for detecting, diagnosing and treating ulcerative interstitial cystitis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1216900C (zh) *	1997-04-11	2005-08-31	桑斯塔特医学有限公司	用于调节免疫系统活性和抑制炎症的细胞调节性亲脂肽
US6696545B1 (en) *	1997-04-11	2004-02-24	Sangstat Medical Corporation	Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
US6232289B1 (en) *	1998-04-17	2001-05-15	University Of Maryland, Baltimore	Method of treating interstitial cytitis with recombinant heparin-binding epidermal growth factor-like growth factor (HB-EGF)
EP1542768A1 (fr) *	2002-09-20	2005-06-22	Alcon, Inc.	Utilisation d'inhibiteurs de la synthese des cytokines dans le traitement des troubles associes a la keratoconjonctivite seche

2003
- 2003-11-17 JP JP2004570638A patent/JP2006516546A/ja active Pending
- 2003-11-17 US US10/535,167 patent/US7671026B2/en not_active Expired - Fee Related
- 2003-11-17 MX MXPA05005101A patent/MXPA05005101A/es not_active Application Discontinuation
- 2003-11-17 AU AU2003294357A patent/AU2003294357A1/en not_active Abandoned
- 2003-11-17 RU RU2005118425/14A patent/RU2005118425A/ru not_active Application Discontinuation
- 2003-11-17 EP EP03789840A patent/EP1594519A4/fr not_active Ceased
- 2003-11-17 KR KR1020057008774A patent/KR20050086676A/ko not_active Withdrawn
- 2003-11-17 CA CA002505922A patent/CA2505922A1/fr not_active Abandoned
- 2003-11-17 BR BR0316290-7A patent/BR0316290A/pt not_active Application Discontinuation
- 2003-11-17 WO PCT/US2003/037043 patent/WO2004045554A2/fr not_active Ceased
2005
- 2005-06-10 NO NO20052814A patent/NO20052814L/no unknown
- 2005-06-14 MA MA28336A patent/MA27607A1/fr unknown
- 2005-06-14 CO CO05057644A patent/CO5640064A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
RU2005118425A (ru)	2006-02-10
EP1594519A2 (fr)	2005-11-16
MA27607A1 (fr)	2005-11-01
MXPA05005101A (es)	2005-09-08
CO5640064A2 (es)	2006-05-31
WO2004045554A2 (fr)	2004-06-03
KR20050086676A (ko)	2005-08-30
CA2505922A1 (fr)	2004-06-03
WO2004045554A3 (fr)	2005-07-07
AU2003294357A1 (en)	2004-06-15
NO20052814D0 (no)	2005-06-10
JP2006516546A (ja)	2006-07-06
US7671026B2 (en)	2010-03-02
BR0316290A (pt)	2005-10-11
EP1594519A4 (fr)	2006-08-16
US20060194738A1 (en)	2006-08-31

Similar Documents

Publication	Publication Date	Title
MY151032A (en)	2014-03-31	Treatment of tnf? related disorders
DE60037394D1 (de)	2008-01-24	VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
CY1116464T1 (el)	2017-03-15	Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
DK1373215T3 (da)	2006-11-13	Gelanamycinderivater egnet til behandling af cancer
MY140767A (en)	2010-01-15	Compounds, methods and compositions
NO20064976L (no)	2006-10-31	Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
WO2001062272A3 (fr)	2002-03-28	Recepteur soluble du facteur de necrose tumorale utilise dans le traitement de certaines affections medicales
MXPA04001187A (es)	2004-07-08	Receptores de interleucina-1 en el tratamiento de enfermedades.
DE602004014117D1 (de)	2008-07-10	Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE322258T1 (de)	2006-04-15	Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren
CY1105080T1 (el)	2009-11-04	Ενωσεις θειενοπυρρολυλιου και φουρανοπυρρολυλιου και η χρηση τους ως συνδετες η4 υποδοχεα ισταμινης
MXPA06000933A (es)	2006-03-30	Compuestos de aminopirazol y uso como inhibidores de chk1.
AU2003225800A1 (en)	2003-09-29	Azolylaminoazine as inhibitors of protein kinases
AU2003218215A1 (en)	2003-09-29	Azolylaminoazines as inhibitors of protein kinases
DK1651161T3 (da)	2012-01-30	Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
SG149027A1 (en)	2009-01-29	Substituted urea derivatives for treating cardiac diseases
CY1107640T1 (el)	2013-04-18	Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
MY140169A (en)	2009-11-30	Compounds, compositions, and methods
NO20052814L (no)	2005-08-04	Cytomodulerende peptider for behandling av interstitielle cystitt
ATE368455T1 (de)	2007-08-15	Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
EA200600921A1 (ru)	2006-10-27	Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
WO2006047716A3 (fr)	2007-05-31	Utilisation d'indoles lies au diindolylmethane et d'inhibiteurs du recepteur de facteur de croissance pour le traitement d'une maladie associee au cytomegalovirus humain
NO20054494L (no)	2006-01-09	Peptidvektorer
ATE411981T1 (de)	2008-11-15	Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
WO2006130679A3 (fr)	2007-08-23	Composition et methode de traitement de rhinite allergique